Editorial

B-Type Natriuretic Peptide in End-Stage Renal Disease: A Neurohormone Rather Than a Volume Status Monitor

Authors: Micha T. Maeder, MD, David M. Kaye, MD, PhD

Abstract

A biomarker assisting in estimating volume status in patients with end-stage renal disease (ESRD) would be very helpful in clinical practice. In this issue of the Southern Medical Journal, Flemmer et al1 evaluated whether changes in B-type natriuretic peptide (BNP), a relatively cardiac-specific 32-amino acid polypeptide released following increased cardiomyocyte stretch and other stimuli, reflect fluid removal during hemodialysis (HD). BNP was measured before and after HD on five occasions in 151 ESRD patients. Although body weight and blood pressure were reduced by HD, there was no change in BNP.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Flemmer MC, et al. Blood B-type natriuretic peptide levels and dialysis: Present assessment and future analyses. South Med J 2008;101:1094–1100.
 
2.Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635–641.
 
3.Gould PA, D’Agostino J, Schneider HG, et al. Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure. Eur J Heart Fail 2006;8:263–269.
 
4.O’Neill JO, Bott-Silverman CE, McRae AT III, et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J 2005;149:363–369.
 
5.Zoccali C, Mallamaci F, Benedetto FA, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12:1508–1515.
 
6.Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005;46:610–620.
 
7.Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003;108:560–565.
 
8.Goetze JP, Jensen G, Moller S, et al. BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest 2006;36:8–15.
 
9.McCullough PA, Duc P, Omland T, et al; Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571–579.
 
10.Maeder MT, Mueller C, Pfisterer ME, et al. Use of B-type natriuretic peptide outside of the emergency department. Int J Cardiol 2008;127:5–16.
 
11.Sheen V, Bhalla V, Tulua-Tata A, et al. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 2007;153:244. e1–e5.
 
12.Wahl HG, Graf S, Renz H, et al. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004;50:1071–1074.
 
13.Maeder M, Wolber T, Rickli H, et al. B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure. Int J Cardiol 2007;120:391–398.
 
14.Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912–1918.
 
15.Zilch O, Vos PF, Oey PL, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens 2007;25:1285–1289.
 
16.Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69:2268–2273.
 
17.Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392–2397.